Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

alpha lipoic acid

- PMLiVE

Genzyme shocked by FDA’s rejection of Lemtrada

US regulator refuses to approve MS drug on safety grounds

- PMLiVE

Sanofi’s Aubagio backed by NICE

Oral MS drug recommended for NHS use in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE wants more info on Genzyme’s MS drug

UK health guidance body turns down Lemtrada in draft guidance

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

Biogen Idec building

Biogen Idec wins EU battle on Tecfidera exclusivity

Oral MS drug gains New Active Substance status

- PMLiVE

Sales down at Merck Serono on Rebif pressure

New MS drugs impact pharma company’s revenues

Biogen Idec building

Rocketing Tecfidera sales give Biogen Idec stellar Q3 results

Oral MS drug on course for blockbuster status in first year

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Sanofi reception

Sanofi wins EU approval for second MS drug in a month

EC approves Lemtrada weeks after Aubagio gets greenlight

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links